Smyth, E. C. et al. Gastric most cancers. Lancet 396(10251), 635–648 (2020).
Liu, N. et al. Identification of novel prognostic biomarkers by integrating multi-omics knowledge in gastric most cancers. BMC Most cancers 21(1), 460 (2021).
Wei, J., Wu, N. D. & Liu, B. R. Regional however deadly: Intraperitoneal metastasis in gastric most cancers. World J. Gastroenterol. 22(33), 7478–7485 (2016).
Tsai, M. M. et al. Potential prognostic, diagnostic and therapeutic markers for human gastric most cancers. World J. Gastroenterol. 20(38), 13791–13803 (2014).
Shimada, H. et al. Medical significance of serum tumor markers for gastric most cancers: A scientific evaluate of literature by the Activity Power of the Japanese Gastric Most cancers Affiliation. Gastric Most cancers 17(1), 26–33 (2014).
Necula, L. et al. Latest advances in gastric most cancers early prognosis. World J. Gastroenterol. 25(17), 2029–2044 (2019).
Rappoport, N. & Shamir, R. Multi-omic and multi-view clustering algorithms: Evaluation and most cancers benchmark. Nucleic Acids Res. 46(20), 10546–10562 (2018).
Luo, N. et al. Prognostic function of M6A-associated immune genes and cluster-related tumor microenvironment evaluation: A multi-omics follow in abdomen adenocarcinoma. Entrance. Cell Dev. Biol. 10, 935135 (2022).
Zhao, J. et al. A multi-omics deep studying mannequin for hypoxia phenotype to foretell tumor aggressiveness and prognosis in uveal melanoma for rationalized hypoxia-targeted remedy. Comput. Struct. Biotechnol. J. 20, 3182–3194 (2022).
Shrestha, R. et al. Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Most cancers Res. 81(7), 1681–1694 (2021).
Lv, S. Q. et al. Complete omics analyses profile genesets associated with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype. Theranostics 12(1), 459–473 (2022).
Zhang, H. & Wu, Z. The generalized Fisher’s mixture and correct p-value calculation beneath dependence. Biometrics 79, 1159–1172 (2022).
Fisher, R. A. Statistical strategies for analysis employees. In Breakthroughs in Statistics 66–70 (Springer, 1992).
Received, S. et al. Selecting an optimum technique to mix P-values. Stat. Med. 28(11), 1537–1553 (2009).
Li, L. et al. The panorama and prognostic worth of tumor-infiltrating immune cells in gastric most cancers. PeerJ 7, e7993 (2019).
Liu, Z. et al. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic advantages in sufferers with muscle invasive bladder most cancers. Oncoimmunology 7(9), e1474317 (2018).
Toor, S. M. et al. Immune checkpoints within the tumor microenvironment. Semin. Most cancers Biol. 65, 1–12 (2020).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq knowledge with DESeq2. Genome Biol. 15(12), 550 (2014).
Hogben, C. A. A sensible and easy equal for Scholar’s T check of statistical significance. J. Lab. Clin. Med. 64, 815–819 (1964).
Kolde, R. & Kolde, M. R. J. R. P. Bundle ‘pheatmap’. 1 (2018).
Yu, G. et al. clusterProfiler: An R bundle for evaluating organic themes amongst gene clusters. OMICS 16(5), 284–287 (2012).
M., C. org.Hs.eg.db: Genome broad annotation for Human. (2015).
Therneau, T. & Grambsch, P. Modeling Survival Information: Extending The Cox Mannequin. vol. 48 (2000).
Kassambara, A. et al. Bundle ‘survminer’ (2017).
Heagerty, P. J., Lumley, T. & Pepe, M. S. J. B. Time‐Dependent ROC Curves for Censored Survival Information and a Diagnostic Marker. vol. 56, no. 2, 337–344 (2000).
Community, T.C.G.A.R. Complete molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014).
Chen, B. et al. Profiling tumor infiltrating immune cells with CIBERSORT. In Most cancers Methods Biology 243–259 (Springer, 2018).
Sohn, B. H. et al. Medical significance of 4 molecular subtypes of gastric most cancers recognized by the most cancers genome atlas undertaking. Clin. Most cancers Res. 23(15), 4441–4449 (2017).
Silva, A. N. S. et al. Growing frequency of gene copy quantity aberrations is related to immunosuppression and predicts poor prognosis in gastric adenocarcinoma. Br. J. Surg. 109(3), 291–297 (2022).
Complete molecular characterization of gastric adenocarcinoma. Nature. 513(7517), 202–209 (2014).
Siegel, R. L., Miller, Okay. D. & Jemal, A. Most cancers statistics, 2016. CA Most cancers J. Clin. 66(1), 7–30 (2016).
Chakraborty, S. et al. Onco-multi-OMICS method: A brand new frontier in most cancers analysis. Biomed. Res. Int. 2018, 9836256 (2018).
Horn, L. A. et al. Reworking the tumor microenvironment by way of blockade of LAIR-1 and TGF-beta signaling permits PD-L1-mediated tumor eradication. J. Clin. Investig. https://doi.org/10.1172/JCI155148 (2022).
Carvalheiro, T. et al. Leukocyte related immunoglobulin like receptor 1 regulation and performance on monocytes and dendritic cells throughout irritation. Entrance. Immunol. 11, 1793 (2020).
Keerthivasan, S. et al. Homeostatic features of monocytes and interstitial lung macrophages are regulated by way of collagen domain-binding receptor LAIR1. Immunity 54(7), 1511-1526.e8 (2021).
Sivori, S. et al. Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of most cancers. Entrance. Immunol. 11, 2156 (2020).
Yang, M. & Brackenbury, W. J. Membrane potential and most cancers development. Entrance. Physiol. 4, 185 (2013).
Silver, B. B. & Nelson, C. M. The bioelectric code: Reprogramming most cancers and growing older from the interface of mechanical and chemical microenvironments. Entrance. Cell Dev. Biol. 6, 21 (2018).
Wang, W. et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian most cancers. Cell 165(5), 1092–1105 (2016).
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung most cancers. N. Engl. J. Med. 378(22), 2078–2092 (2018).
Lan, X. et al. Elevated BTLA and HVEM in gastric most cancers are related to development and poor prognosis. Onco Targets Ther. 10, 919–926 (2017).
Nagai, S. & Azuma, M. The CD28-B7 household of co-signaling molecules. Adv. Exp. Med. Biol. 1189, 25–51 (2019).
Beckermann, Okay. E. et al. CD28 costimulation drives tumor-infiltrating T cell glycolysis to advertise irritation. JCI Perception https://doi.org/10.1172/jci.perception.138729 (2020).
Teijeira, A. et al. Metabolic penalties of T-cell costimulation in anticancer immunity. Most cancers Immunol. Res. 7(10), 1564–1569 (2019).
Marangoni, F. et al. Tumor tolerance-promoting perform of regulatory T cells is optimized by CD28, however strictly depending on calcineurin. J. Immunol. 200(10), 3647–3661 (2018).
Flemming, A. T cells: Profitable checkpoint blockade requires optimistic co-stimulation. Nat. Rev. Immunol. 17(4), 215 (2017).
Hui, E. et al. T cell costimulatory receptor CD28 is a main goal for PD-1-mediated inhibition. Science 355(6332), 1428–1433 (2017).
Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355(6332), 1423–1427 (2017).
Kim, Okay. H. et al. PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by lack of CD28 expression and rescued by IL-15. Cell Mol. Immunol. 18(2), 385–397 (2021).
Wherry, E. J. & Kurachi, M. Molecular and mobile insights into T cell exhaustion. Nat. Rev. Immunol. 15(8), 486–499 (2015).
Bucktrout, S. L., Bluestone, J. A. & Ramsdell, F. Latest advances in immunotherapies: From an infection and autoimmunity, to most cancers, and again once more. Genome Med. 10(1), 79 (2018).
Meyaard, L. The inhibitory collagen receptor LAIR-1 (CD305). J. Leukoc. Biol. 83(4), 799–803 (2008).
Lebbink, R. J. et al. Identification of a number of potent binding websites for human leukocyte related Ig-like receptor LAIR on collagens II and III. Matrix Biol. 28(4), 202–210 (2009).
Peng, D. H. et al. Collagen promotes anti-PD-1/PD-L1 resistance in most cancers by way of LAIR1-dependent CD8(+) T cell exhaustion. Nat. Commun. 11(1), 4520 (2020).
Croft, M. Management of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57–78 (2010).
Martins, M. R. et al. May OX40 agonist antibody promote activation of the anti-tumor immune response in gastric most cancers?. J. Surg. Oncol. 117(5), 840–844 (2018).
Lima, C. A. C. et al. Excessive soluble OX40 ranges correlate with metastatic gastric most cancers. J. Surg. Oncol. 126(1), 139–143 (2022).
Li, Y. et al. Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma by way of inhibiting apoptosis of tumor cells. Most cancers Lett. 497, 212–220 (2021).
Roszik, J. et al. TNFSF4 (OX40L) expression and survival in regionally superior and metastatic melanoma. Most cancers Immunol. Immunother. 68(9), 1493–1500 (2019).
Shah, S. C. et al. Inhabitants-based evaluation of variations in gastric most cancers incidence amongst races and ethnicities in people age 50 years and older. Gastroenterology 159(5), 1705-1714.e2 (2020).
Gao, S. et al. Results of HCG on human epithelial ovarian most cancers vasculogenic mimicry formation in vivo. Oncol. Lett. 12(1), 459–466 (2016).
Wang, W. et al. An affiliation between genetic polymorphisms within the ileal sodium-dependent bile acid transporter gene and the danger of colorectal adenomas. Most cancers Epidemiol. Biomark. Prev. 10(9), 931–936 (2001).
Zhou, C. L., Su, H. L. & Dai, H. W. Thrombopoietin is related to a prognosis of gastric adenocarcinoma. Rev. Assoc. Med. Bras. (1992) 66(5), 590–595 (2020).
Guo, Y. et al. Clinicopathological significance of platelet-derived development issue B, platelet-derived development issue recpertor-β, and E-cadherin expression in gastric carcinoma. Contemp. Oncol./Współczesna Onkologia 17(2), 150–155 (2013).
Gong, Y., Chen, L. & Chu, X. Expression of platelet-derived development issue and PDGF receptors and its native invasiveness and metwastasis in human pancreatic most cancers. J.-Nanjing Univ. Nat. Sci. Ed. 34, 564–568 (1998).
Wang, G. et al. Hypomethylated gene NRP1 is co-expressed with PDGFRB and related to poor total survival in gastric most cancers sufferers. Biomed. Pharmacother. 111, 1334–1341 (2019).
Wu, M., Li, Q. & Wang, H. Identification of novel biomarkers related to the prognosis and potential pathogenesis of breast most cancers by way of built-in bioinformatics evaluation. Technol. Most cancers Res. Deal with. 20, 1533033821992081 (2021).
Soiland, H. et al. Apolipoprotein D predicts antagonistic final result in girls > or =70 years with operable breast most cancers. Breast Most cancers Res. Deal with. 113(3), 519–528 (2009).
Mitchel, J. et al. A translational pipeline for total survival prediction of breast most cancers sufferers by decision-level integration of multi-omics knowledge. In Proceedings (IEEE Int Conf Bioinformatics Biomed), 2019, 1573–1580 (2019).
Zhang, J. et al. Regulation of docetaxel chemosensitivity by NR2F6 in breast most cancers. Endocr. Relat. Most cancers 27(5), 309–323 (2020).
Deeken, J. F. et al. A pharmacogenetic examine of docetaxel and thalidomide in sufferers with castration-resistant prostate most cancers utilizing the DMET genotyping platform. Pharmacogenomics J. 10(3), 191–199 (2010).
